Press releases

Companies intend to continue a pre-existing collaboration in the development of less-invasive surgical tools for the treatment of arrhythmias, particularly atrial fibrillation.

Analyst meeting on Monday, February 23 will focus on the Company's outlook for 2004 and beyond.

New 120,000 square-foot building at the Maple Grove campus will house primarily research and development laboratories and offices.

Site will initially serve as the new headquarters for the Company's growing Endosurgery group.

FDA team indicated it intends to recommend approval to manufacture the TAXUS™ Express2™ paclitaxel-eluting coronary stent system for the U.S. market.